Alta Capital Management LLC Trims Stock Position in IDEXX Laboratories, Inc. $IDXX

Alta Capital Management LLC trimmed its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 53.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,202 shares of the company’s stock after selling 11,941 shares during the quarter. Alta Capital Management LLC’s holdings in IDEXX Laboratories were worth $6,518,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. J.Safra Asset Management Corp purchased a new position in IDEXX Laboratories in the third quarter worth approximately $31,000. Armstrong Advisory Group Inc. raised its position in IDEXX Laboratories by 55.9% in the third quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock valued at $34,000 after purchasing an additional 19 shares during the period. Salomon & Ludwin LLC acquired a new position in shares of IDEXX Laboratories in the 3rd quarter valued at $35,000. Greykasell Wealth Strategies Inc. purchased a new position in shares of IDEXX Laboratories during the 3rd quarter worth $35,000. Finally, WealthCollab LLC purchased a new position in shares of IDEXX Laboratories during the 2nd quarter worth $30,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Buying and Selling

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 9,425 shares of the stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $703.34, for a total value of $6,628,979.50. Following the sale, the executive vice president directly owned 21,149 shares of the company’s stock, valued at approximately $14,874,937.66. This represents a 30.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. 0.98% of the stock is owned by company insiders.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $632.56 on Wednesday. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.87. The company has a market cap of $50.51 billion, a price-to-earnings ratio of 48.40, a price-to-earnings-growth ratio of 3.41 and a beta of 1.67. The stock’s 50-day moving average is $700.41 and its two-hundred day moving average is $663.48. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Monday, February 2nd. The company reported $3.08 EPS for the quarter, topping analysts’ consensus estimates of $2.93 by $0.15. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The business had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the previous year, the company posted $2.53 earnings per share. The business’s revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on IDXX shares. JPMorgan Chase & Co. upped their target price on shares of IDEXX Laboratories from $675.00 to $775.00 and gave the company an “overweight” rating in a research report on Tuesday, November 4th. Leerink Partners set a $785.00 price objective on shares of IDEXX Laboratories in a report on Monday, November 3rd. Jefferies Financial Group reissued a “buy” rating and issued a $830.00 target price on shares of IDEXX Laboratories in a research report on Tuesday, November 4th. Morgan Stanley upped their price target on IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. Finally, Weiss Ratings cut IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, January 29th. Seven analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $783.33.

IDEXX Laboratories News Summary

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: IDXX beat Q4 expectations — reported $3.08 EPS vs. $2.93 consensus and $1.091B revenue, with margins improving and double-digit year-over-year revenue growth; this underscores resilient demand in core diagnostics. Business Wire: IDEXX Announces Fourth Quarter and Full-Year 2025 Results
• Positive Sentiment: Companion Animal Group (CAG) and Water businesses showed strong growth (CAG ~15% reported; Water ~12%), and management highlighted innovation and higher tests per visit as growth drivers — supporting mid/long-term revenue expansion. Seeking Alpha: Idexx targets $4.632B–$4.720B revenue for 2026
• Neutral Sentiment: Management issued FY2026 guidance (EPS range 14.290–14.800, revenue $4.6B–$4.7B); the EPS range is roughly in line with Street expectations while revenue guidance is at/just below consensus, leaving room for interpretation. Reuters: IDEXX forecasts 2026 revenue, profit above estimates
• Neutral Sentiment: Full earnings call transcripts and slide deck are available; management commentary reiterates innovation-led growth and clinic testing intensity as key assumptions — useful for modeling but not immediately market-moving. MSN: IDEXX Q4 2025 earnings call transcript
• Negative Sentiment: Some analysts trimmed forecasts after the print and guidance, signaling lowered near-term expectations and prompting downward pressure on the stock. Benzinga: Analysts Cut Their Forecasts Following Q4 Results
• Negative Sentiment: Market reaction focused on the outlook: despite a beat, commentary and the revenue range prompted investors to pare positions, with coverage noting shares trimmed on the guidance nuance. MSN: IDEXX tops revenue forecasts, shares edge lower on outlook

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.